User login
Key clinical point: Adding atezolizumab to carboplatin improved overall survival (OS) outcomes in patients with metastatic triple-negative breast cancer (TNBC).
Major finding: Compared with carboplatin alone, carboplatin + atezolizumab demonstrated significant improvement in OS outcomes (hazard ratio [HR] 0.60; log-rank P = .03) even though the improvement in the primary endpoint of progression-free survival was not statistically significant (HR 0.66; log-rank P = .05). The prevalence of grade 3/4 serious adverse events was higher with carboplatin + atezolizumab vs carboplatin alone (41% vs 8%).
Study details: Findings are from the phase 2 TBCRC 043 trial that included 106 patients with metastatic TNBC who were randomly assigned to receive either carboplatin alone or in combination with atezolizumab.
Disclosures: This study was supported by a US National Cancer Institute grant, Susan G. Komen grants, and other sources. Some authors declared receiving grants or personal fees from or having other ties with various sources, including the funding agencies.
Source: Lehmann BD et al. Atezolizumab in combination with carboplatin and survival outcomes in patients with metastatic triple-negative breast cancer: The TBCRC 043 phase 2 randomized clinical trial. JAMA Oncol. 2023 (Dec 14). doi: 10.1001/jamaoncol.2023.5424
Key clinical point: Adding atezolizumab to carboplatin improved overall survival (OS) outcomes in patients with metastatic triple-negative breast cancer (TNBC).
Major finding: Compared with carboplatin alone, carboplatin + atezolizumab demonstrated significant improvement in OS outcomes (hazard ratio [HR] 0.60; log-rank P = .03) even though the improvement in the primary endpoint of progression-free survival was not statistically significant (HR 0.66; log-rank P = .05). The prevalence of grade 3/4 serious adverse events was higher with carboplatin + atezolizumab vs carboplatin alone (41% vs 8%).
Study details: Findings are from the phase 2 TBCRC 043 trial that included 106 patients with metastatic TNBC who were randomly assigned to receive either carboplatin alone or in combination with atezolizumab.
Disclosures: This study was supported by a US National Cancer Institute grant, Susan G. Komen grants, and other sources. Some authors declared receiving grants or personal fees from or having other ties with various sources, including the funding agencies.
Source: Lehmann BD et al. Atezolizumab in combination with carboplatin and survival outcomes in patients with metastatic triple-negative breast cancer: The TBCRC 043 phase 2 randomized clinical trial. JAMA Oncol. 2023 (Dec 14). doi: 10.1001/jamaoncol.2023.5424
Key clinical point: Adding atezolizumab to carboplatin improved overall survival (OS) outcomes in patients with metastatic triple-negative breast cancer (TNBC).
Major finding: Compared with carboplatin alone, carboplatin + atezolizumab demonstrated significant improvement in OS outcomes (hazard ratio [HR] 0.60; log-rank P = .03) even though the improvement in the primary endpoint of progression-free survival was not statistically significant (HR 0.66; log-rank P = .05). The prevalence of grade 3/4 serious adverse events was higher with carboplatin + atezolizumab vs carboplatin alone (41% vs 8%).
Study details: Findings are from the phase 2 TBCRC 043 trial that included 106 patients with metastatic TNBC who were randomly assigned to receive either carboplatin alone or in combination with atezolizumab.
Disclosures: This study was supported by a US National Cancer Institute grant, Susan G. Komen grants, and other sources. Some authors declared receiving grants or personal fees from or having other ties with various sources, including the funding agencies.
Source: Lehmann BD et al. Atezolizumab in combination with carboplatin and survival outcomes in patients with metastatic triple-negative breast cancer: The TBCRC 043 phase 2 randomized clinical trial. JAMA Oncol. 2023 (Dec 14). doi: 10.1001/jamaoncol.2023.5424